BMS laying off, while Geron continues it's hiring spree....

[kmall]

A little bit like comparing apples to oranges when taking Geron on a head to head comparison with a behemoth like Bristol Meyers. However, BMS just announced they are laying off an additional 100+ employees after sales estimates missed by $1B in the instance of Revlimid (lenalidomide), which is targeting "the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities."

"Sales projections for Revlimid were cut by $1 billion."

Of course all of us living in Geronlandia are expecting Imetelstat to become a formidable opponent in the Hematological space. Many eyes are watching in anticipation. -Kmall


https://www.fiercepharma.com/pharma/bms ... r-earnings